within Pharmacolibrary.Drugs.ATC.N;

model N05CM05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 1.23 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.4 / 1000000,
    adminCount     = 1,
    Vd             = 0.0087,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Scopolamine is an anticholinergic agent used to prevent nausea and vomiting caused by motion sickness or anesthesia and surgery. It acts as a competitive antagonist of muscarinic acetylcholine receptors. Scopolamine is approved and used today, commonly administered via transdermal patches or other parenteral routes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Renner, UD, Oertel, R, &amp; Kirch, W (2005). Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. <i>Therapeutic drug monitoring</i> 27(5) 655–665. DOI:<a href=&quot;https://doi.org/10.1097/01.ftd.0000168293.48226.57&quot;>10.1097/01.ftd.0000168293.48226.57</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16175141/&quot;>https://pubmed.ncbi.nlm.nih.gov/16175141</a></p></li><li><p>Putcha, L, Cintrón, NM, Tsui, J, Vanderploeg, JM, &amp; Kramer, WG (1989). Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. <i>Pharmaceutical research</i> 6(6) 481–485. DOI:<a href=&quot;https://doi.org/10.1023/a:1015916423156&quot;>10.1023/a:1015916423156</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2762223/&quot;>https://pubmed.ncbi.nlm.nih.gov/2762223</a></p></li><li><p>Nachum, Z, Shupak, A, &amp; Gordon, CR (2006). Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. <i>Clinical pharmacokinetics</i> 45(6) 543–566. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200645060-00001&quot;>10.2165/00003088-200645060-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16719539/&quot;>https://pubmed.ncbi.nlm.nih.gov/16719539</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05CM05;
